161 related articles for article (PubMed ID: 22880162)
1. Development of Chlamydial Type III Secretion System Inhibitors for Suppression of Acute and Chronic Forms of Chlamydial Infection.
Zigangirova NA; Zayakin ES; Kapotina LN; Kost EA; Didenko LV; Davydova DY; Rumyanceva JP; Gintsburg AL
Acta Naturae; 2012 Apr; 4(2):87-97. PubMed ID: 22880162
[TBL] [Abstract][Full Text] [Related]
2. Identification of chlamydial T3SS inhibitors through virtual screening against T3SS ATPase.
Grishin AV; Luyksaar SI; Kapotina LN; Kirsanov DD; Zayakin ES; Karyagina AS; Zigangirova NA
Chem Biol Drug Des; 2018 Mar; 91(3):717-727. PubMed ID: 29068165
[TBL] [Abstract][Full Text] [Related]
3. An Experimental Pipeline for Initial Characterization of Bacterial Type III Secretion System Inhibitor Mode of Action Using Enteropathogenic
Morgan JM; Lam HN; Delgado J; Luu J; Mohammadi S; Isberg RR; Wang H; Auerbuch V
Front Cell Infect Microbiol; 2018; 8():404. PubMed ID: 30524970
[TBL] [Abstract][Full Text] [Related]
4. Context-Dependent Action of Scc4 Reinforces Control of the Type III Secretion System.
Gao L; Cong Y; Plano GV; Rao X; Gisclair LN; Schesser Bartra S; Macnaughtan MA; Shen L
J Bacteriol; 2020 Jul; 202(15):. PubMed ID: 32424009
[No Abstract] [Full Text] [Related]
5. Developing Cyclic Peptomers as Broad-Spectrum Type III Secretion System Inhibitors in Gram-Negative Bacteria.
Lam HN; Lau T; Lentz A; Sherry J; Cabrera-Cortez A; Hug K; Lalljie A; Engel J; Lokey RS; Auerbuch V
Antimicrob Agents Chemother; 2021 Jun; 65(7):e0169020. PubMed ID: 33875435
[TBL] [Abstract][Full Text] [Related]
6. Conserved type III secretion system exerts important roles in Chlamydia trachomatis.
Dai W; Li Z
Int J Clin Exp Pathol; 2014; 7(9):5404-14. PubMed ID: 25337183
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Chlamydia trachomatis with a small molecule inhibitor of the Yersinia type III secretion system disrupts progression of the chlamydial developmental cycle.
Wolf K; Betts HJ; Chellas-Géry B; Hower S; Linton CN; Fields KA
Mol Microbiol; 2006 Sep; 61(6):1543-55. PubMed ID: 16968227
[TBL] [Abstract][Full Text] [Related]
8. [The role of the type-three secretion system of the gram-negative bacteria in regulation of chronic infections].
Zigangirova NA; Nesterenko LN; Tiganova IG; Kost EA
Mol Gen Mikrobiol Virusol; 2012; (3):3-13. PubMed ID: 22984766
[TBL] [Abstract][Full Text] [Related]
9. Small-Molecule Inhibitors of the Type III Secretion System.
Gu L; Zhou S; Zhu L; Liang C; Chen X
Molecules; 2015 Sep; 20(9):17659-74. PubMed ID: 26404233
[TBL] [Abstract][Full Text] [Related]
10. Virulence blockers as alternatives to antibiotics: type III secretion inhibitors against Gram-negative bacteria.
Keyser P; Elofsson M; Rosell S; Wolf-Watz H
J Intern Med; 2008 Jul; 264(1):17-29. PubMed ID: 18393958
[TBL] [Abstract][Full Text] [Related]
11. The bacterial type III secretion system as a target for developing new antibiotics.
McShan AC; De Guzman RN
Chem Biol Drug Des; 2015 Jan; 85(1):30-42. PubMed ID: 25521643
[TBL] [Abstract][Full Text] [Related]
12. Piericidin A1 Blocks
Morgan JM; Duncan MC; Johnson KS; Diepold A; Lam H; Dupzyk AJ; Martin LR; Wong WR; Armitage JP; Linington RG; Auerbuch V
mSphere; 2017; 2(1):. PubMed ID: 28217742
[TBL] [Abstract][Full Text] [Related]
13. A Structure-Function-Inhibition Analysis of the
Moir DT; Bowlin NO; Berube BJ; Yabut J; Mills DM; Nguyen GT; Aron ZD; Williams JD; Mecsas J; Hauser AR; Bowlin TL
J Bacteriol; 2020 Aug; 202(18):. PubMed ID: 32601072
[TBL] [Abstract][Full Text] [Related]
14. Molecular Characterization of the ClpC AAA+ ATPase in the Biology of Chlamydia trachomatis.
Pan S; Jensen AA; Wood NA; Henrichfreise B; Brötz-Oesterhelt H; Fisher DJ; Sass P; Ouellette SP
mBio; 2023 Apr; 14(2):e0007523. PubMed ID: 36975997
[TBL] [Abstract][Full Text] [Related]
15. Innovation and Application of the Type III Secretion System Inhibitors in Plant Pathogenic Bacteria.
Yuan X; Yu M; Yang CH
Microorganisms; 2020 Dec; 8(12):. PubMed ID: 33317075
[TBL] [Abstract][Full Text] [Related]
16. Research Progress on Small Molecular Inhibitors of the Type 3 Secretion System.
Lv C; Li Y; Wei Y; Wang J; Yu H; Gao F; Zhu C; Jia X; Tong M; Dong P; Gao Q; Geng L
Molecules; 2022 Nov; 27(23):. PubMed ID: 36500441
[TBL] [Abstract][Full Text] [Related]
17. Benzylidene acylhydrazides inhibit chlamydial growth in a type III secretion- and iron chelation-independent manner.
Bao X; Gylfe A; Sturdevant GL; Gong Z; Xu S; Caldwell HD; Elofsson M; Fan H
J Bacteriol; 2014 Aug; 196(16):2989-3001. PubMed ID: 24914180
[TBL] [Abstract][Full Text] [Related]
18. A novel strategy to control Pseudomonas syringae through inhibition of type III secretion system.
He LL; Wang X; O'Neill Rothenberg D; Xu X; Wang HH; Deng X; Cui ZN
Pestic Biochem Physiol; 2023 Aug; 194():105471. PubMed ID: 37532345
[TBL] [Abstract][Full Text] [Related]
19. Identification of Benzyloxy Carbonimidoyl Dicyanide Derivatives as Novel Type III Secretion System Inhibitors
Ma YN; Chen L; Si NG; Jiang WJ; Zhou ZG; Liu JL; Zhang LQ
Front Plant Sci; 2019; 10():1059. PubMed ID: 31543889
[TBL] [Abstract][Full Text] [Related]
20. Novel Disk Diffusion Assay on Magnesium Oxalate Agar To Evaluate the Susceptibility of Yersinia pestis to Type III Secretion System Inhibitors.
Prashar S; Portales Guemes M; Shivbaran P; Jimenez Alvarez E; Soha C; Nacer S; McDonough M; Plano GV; Torruellas Garcia J
Microbiol Spectr; 2021 Sep; 9(1):e0000521. PubMed ID: 34132578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
